The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis

被引：41
|
作者：
Madsen, Claus [1 ]
机构：
[1] Odense Univ Hosp, Dept Neurol, Odense C, Denmark
来源：
BRAIN AND BEHAVIOR | 2017年 / 7卷 / 06期
关键词：
interferon beta; multiple sclerosis; peginterferon beta-1a; RRMS; DISEASE-MODIFYING THERAPIES; NEUTRALIZING ANTIBODIES; PEGINTERFERON BETA-1A; ADHERENCE; NEOPTERIN; IMPACT; PHARMACOLOGY; PREGNANCY; OUTCOMES; MARKER;
D O I：
10.1002/brb3.696
中图分类号：
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号：
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要：
The introduction of interferon beta therapies more than 20 years ago marked a milestone in the treatment of relapsing-remitting multiple sclerosis (RRMS) with a significant impact on the approach to modern multiple sclerosis (MS) care. Key learnings and perspectives from the early days of disease modifying therapies in MS have improved the knowledge base of MS, need for treatment, and patient care. The continuous development of interferons over the past two decades outlines a journey with increased understanding of the pharmacodynamics and pharmacokinetic mechanisms of interferons, leading to innovative formulations with an improved benefit/risk profile.
引用
收藏
页数：8
相关论文
共 50 条
  • [1] The use of interferon beta in relapsing-remitting multiple sclerosis
    Etheridge, LJ
    Beverley, DW
    Ferrie, C
    McManus, E
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2004, 89 (08) : 789 - 791
  • [2] A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis
    Goodin, Douglas S.
    [J]. NEUROLOGY, 2006, 67 (07) : 1313 - 1313
  • [3] A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis
    Koch-Henriksen, N
    Sorensen, PS
    Christensen, T
    Frederiksen, J
    Ravnborg, M
    Jensen, K
    Heltberg, A
    Kristensen, O
    Stenager, E
    Petersen, T
    Hansen, T
    [J]. NEUROLOGY, 2006, 66 (07) : 1056 - 1060
  • [4] Interferon beta-1a in relapsing-remitting multiple sclerosis
    Blumhardt, L
    [J]. HOSPITAL MEDICINE, 1999, 60 (03): : 192 - 195
  • [5] Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis
    Greenberg, Benjamin M.
    Balcer, Laura
    Calabresi, Peter A.
    Cree, Bruce
    Cross, Anne
    Frohman, Teresa
    Gold, Ralf
    Havrdova, Eva
    Hemmer, Bernhard
    Kieseier, Bernd C.
    Lisak, Robert
    Miller, Aaron
    Racke, Michael K.
    Steinman, Lawrence
    Stuve, Olaf
    Wiendl, Heinz
    Frohman, Elliot
    [J]. JAMA NEUROLOGY, 2013, 70 (02) : 248 - 251
  • [6] Impact of discontinuing interferon beta in patients with relapsing-remitting multiple sclerosis
    Agiela, Mabroka I. M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
  • [7] Predicting beta-interferon failure in relapsing-remitting multiple sclerosis
    O'Rourke, K.
    Walsh, C.
    Antonelli, G.
    Hutchinson, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (03) : 336 - 342
  • [8] Interferon-beta and disability progression in relapsing-remitting multiple sclerosis
    Drulovic, Jelena
    Kostic, Jelena
    Mesaros, Sarlota
    Basuroski, Irena Dujmovic
    Stojsavljevic, Nebojsa
    Kisic-Tepavcevic, Darija
    Pekmezovic, Tatjana
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 : S65 - S69
  • [9] Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
    Cocco, Eleonora
    Marrosu, Maria Giovanna
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 759 - 766
  • [10] Methodological considerations in a meta analysis of interferon treatments in relapsing-remitting multiple sclerosis
    Mikol, DD
    [J]. ANNALS OF NEUROLOGY, 2003, 54 : S61 - S61
12345